Bruderer S - Search Results

1

De Lorenzi F, Weinmann T, Bruderer S, Heitmann B, Henrici A, Stingelin S. De Lorenzi F, et al. Among authors: bruderer s. J Magn Reson. 2024 Jul;364:107723. doi: 10.1016/j.jmr.2024.107723. Epub 2024 Jun 15. J Magn Reson. 2024. PMID: 38936240 Free article.

2

Automatic classification of signal regions in ¹H Nuclear Magnetic Resonance spectra.

Fischetti G, Schmid N, Bruderer S, Caldarelli G, Scarso A, Henrici A, Wilhelm D. Fischetti G, et al. Among authors: bruderer s. Front Artif Intell. 2023 Jan 11;5:1116416. doi: 10.3389/frai.2022.1116416. eCollection 2022. Front Artif Intell. 2023. PMID: 36714208 Free PMC article.

3

Deconvolution of 1D NMR spectra: A deep learning-based approach.

Schmid N, Bruderer S, Paruzzo F, Fischetti G, Toscano G, Graf D, Fey M, Henrici A, Ziebart V, Heitmann B, Grabner H, Wegner JD, Sigel RKO, Wilhelm D. Schmid N, et al. Among authors: bruderer s. J Magn Reson. 2023 Feb;347:107357. doi: 10.1016/j.jmr.2022.107357. Epub 2022 Dec 8. J Magn Reson. 2023. PMID: 36563418 Free article.

4

Clopidogrel, a CYP2C8 inhibitor, causes a clinically relevant increase in the systemic exposure to the active metabolite of selexipag in healthy subjects.

Axelsen LN, Poggesi I, Rasschaert F, Perez Ruixo JJ, Bruderer S. Axelsen LN, et al. Among authors: bruderer s. Br J Clin Pharmacol. 2021 Jan;87(1):119-128. doi: 10.1111/bcp.14365. Epub 2020 Jun 5. Br J Clin Pharmacol. 2021. PMID: 32415684 Free PMC article.

5

Bioequivalence of macitentan and tadalafil given as fixed-dose combination or single-component tablets in healthy subjects.

Grill S, Bruderer S, Sidharta PN, Antonova M, Globig S, Carlson J, Schultz A, Csonka D. Grill S, et al. Among authors: bruderer s. Br J Clin Pharmacol. 2020 Dec;86(12):2424-2434. doi: 10.1111/bcp.14347. Epub 2020 May 29. Br J Clin Pharmacol. 2020. PMID: 32374030 Free PMC article.

6

Effect of Macitentan on the Pharmacokinetics of the Breast Cancer Resistance Protein Substrates, Rosuvastatin and Riociguat, in Healthy Male Subjects.

Csonka D, Bruderer S, Schultz A, Soergel M, Stepanova R, Sabattini G, Perez-Ruixo JJ. Csonka D, et al. Among authors: bruderer s. Clin Drug Investig. 2019 Dec;39(12):1223-1232. doi: 10.1007/s40261-019-00857-7. Clin Drug Investig. 2019. PMID: 31552642 Free PMC article.

7

Population-Based Study on the Epidemiology of Ménière's Disease.

Bruderer SG, Bodmer D, Stohler NA, Jick SS, Meier CR. Bruderer SG, et al. Audiol Neurootol. 2017;22(2):74-82. doi: 10.1159/000475875. Epub 2017 Jul 20. Audiol Neurootol. 2017. PMID: 28723686

8

Effect of gemfibrozil and rifampicin on the pharmacokinetics of selexipag and its active metabolite in healthy subjects.

Bruderer S, Petersen-Sylla M, Boehler M, Remeňová T, Halabi A, Dingemanse J. Bruderer S, et al. Br J Clin Pharmacol. 2017 Dec;83(12):2778-2788. doi: 10.1111/bcp.13379. Epub 2017 Aug 16. Br J Clin Pharmacol. 2017. PMID: 28715853 Free PMC article. Clinical Trial.

9

Biocomparison Study of Adult and Paediatric Dose Strengths of the Prostacyclin Receptor Agonist Selexipag.

Boehler M, Bruderer S, Ulč I, Dingemanse J. Boehler M, et al. Among authors: bruderer s. Eur J Drug Metab Pharmacokinet. 2018 Feb;43(1):115-120. doi: 10.1007/s13318-017-0424-z. Eur J Drug Metab Pharmacokinet. 2018. PMID: 28639216 Clinical Trial.

10

A pharmacokinetic drug-drug interaction study between selexipag and midazolam, a CYP3A4 substrate, in healthy male subjects.

Juif PE, Boehler M, Donazzolo Y, Bruderer S, Dingemanse J. Juif PE, et al. Among authors: bruderer s. Eur J Clin Pharmacol. 2017 Sep;73(9):1121-1128. doi: 10.1007/s00228-017-2282-7. Epub 2017 Jun 21. Eur J Clin Pharmacol. 2017. PMID: 28639119 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

36 results

Search Page

Filters